Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

T. Haak; T. Meinicke; R. Jones; S. Weber; M. von Eynatten; H.-J. Woerle

doi:10.1111/j.1463-1326.2012.01590.x

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2012.01590.x ◽

2012 ◽

Vol 14 (6) ◽

pp. 565-574 ◽

Cited By ~ 96

Author(s):

T. Haak ◽

T. Meinicke ◽

R. Jones ◽

S. Weber ◽

M. von Eynatten ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination

Download Full-text

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Diabetic Medicine ◽

10.1111/j.1464-5491.2012.03745.x ◽

2012 ◽

Vol 29 (10) ◽

pp. 1260-1267 ◽

Cited By ~ 61

Author(s):

G. Grunberger ◽

A. Chang ◽

G. Garcia Soria ◽

F. T. Botros ◽

R. Bsharat ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01391.x ◽

2011 ◽

Vol 13 (7) ◽

pp. 653-661 ◽

Cited By ~ 117

Author(s):

R. Gomis ◽

R.-M. Espadero ◽

R. Jones ◽

H. J. Woerle ◽

K. A. Dugi

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination Therapy ◽

Initial Combination

Download Full-text

Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2009.01159.x ◽

2010 ◽

Vol 12 (3) ◽

pp. 246-251 ◽

Cited By ~ 20

Author(s):

K. Kondo ◽

T. Kadowaki

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Ldl Cholesterol ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Cholesterol Levels

Download Full-text

Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study

Indian Journal of Endocrinology and Metabolism ◽

10.4103/2230-8210.149319 ◽

2015 ◽

Vol 19 (2) ◽

pp. 256 ◽

Cited By ~ 1

Author(s):

Vaishali Deshmukh ◽

Srikanta Sathyanarayana ◽

Shalini Menon ◽

Shiva Patil ◽

Russel Jones ◽

...

Keyword(s):

Type 2 Diabetes ◽

Subgroup Analysis ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Indian Patients ◽

Initial Combination

Download Full-text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Endocrine Journal ◽

10.1507/endocrj.ej14-0147 ◽

2014 ◽

Vol 61 (10) ◽

pp. 949-959 ◽

Cited By ~ 28

Author(s):

Yasuo Terauchi ◽

Yoichi Satoi ◽

Masakazu Takeuchi ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

The effects of vitamin D2 or D3supplementation on glycaemic control and related metabolic parameters in people at risk of type 2 diabetes: protocol of a randomised double-blind placebo-controlled trial

BMC Public Health ◽

10.1186/1471-2458-13-999 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 3

Author(s):

Ravi K Menon ◽

Anna P Rickard ◽

Nasima Mannan ◽

Peter M Timms ◽

Stephen J Sharp ◽

...

Keyword(s):

Type 2 Diabetes ◽

At Risk ◽

Glycaemic Control ◽

Controlled Trial ◽

Metabolic Parameters ◽

Vitamin D2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD)

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.02.030 ◽

2018 ◽

Vol 271 ◽

pp. 148-155 ◽

Cited By ~ 12

Author(s):

Aleksander Siniarski ◽

Maciej Haberka ◽

Magdalena Mostowik ◽

Renata Gołębiowska-Wiatrak ◽

Małgorzata Poręba ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acids ◽

Cardiovascular Risk ◽

Controlled Study ◽

Omega 3 ◽

High Cardiovascular Risk ◽

Double Blind ◽

Double Blind Placebo ◽

Very High

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text